NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC): Nasdaq/NYSE listing notice — NeuroOne Medical receives Nasdaq extension to May 4, 2026 to regain $1.00 bid price compliance

NEUROONE MEDICAL TECHNOLOGIES Corp

Nasdaq granted a 180-day extension until May 4, 2026 for minimum bid price compliance.
Company previously disclosed non-compliance on May 9, 2025; initial cure period expired Nov 3, 2025.
If not compliant by May 4, 2026, Nasdaq may delist; company can appeal to a hearing panel.
Listing remains fully effective during extension; no immediate impact on common stock trading.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

NEUROONE MEDICAL TECHNOLOGIES Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 4, 2025, NeuroOne Medical Technologies Corporation (the “Company”) received a letter (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company a 180-day extension, until May 4, 2026 (the “Extension Period”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“Common Stock”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Mi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-25-106454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.